Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell unloaded 5,145 shares of the stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $157.88, for a total transaction of $812,292.60. Following the completion of the sale, the chief executive officer now directly owns 1,027,186 shares in the company, valued at approximately $162,172,126. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.52% on Tuesday, hitting $156.46. 1,300,759 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52 week low of $100.89 and a 52 week high of $185.43. The stock’s 50-day moving average is $161.9 and its 200-day moving average is $161.1. The company has a market cap of $30.950 billion and a P/E ratio of 79.63.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.

ALXN has been the subject of a number of recent research reports. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $183.00.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.